Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy
- PMID: 20451638
- PMCID: PMC3870157
- DOI: 10.1016/j.vaccine.2010.04.074
Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy
Abstract
Premature death of the adoptively transferred cytolytic T lymphocytes (CTL) by means of activation induced cell death (AICD) represents one of the major constraints in devising an effective anti-cancer immune intervention strategy. Understanding the mechanism of AICD is, therefore, critical for developing methods to interfere with this death process. Although the existing paradigm on AICD centers around the initiation of the cascade of events originating from the engagement of death receptors leading to the activation of effector caspases and eventually resulting in cell death, recent findings have questioned the universal role of caspases as the cell death executioners. We here review our current understanding of the contribution of caspase-dependent and caspase-independent death executioners in AICD of T cells. We will also discuss the involvement of mitochondria-centric death pathway in AICD of human tumor associated antigen-specific primary CTL and its implications in cancer immunotherapy.
(c) 2010 Elsevier Ltd. All rights reserved.
Figures


Similar articles
-
Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53.Expert Opin Ther Targets. 2017 Feb;21(2):117-129. doi: 10.1080/14728222.2017.1270941. Epub 2016 Dec 20. Expert Opin Ther Targets. 2017. PMID: 27935327
-
Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy.J Immunol. 2004 Nov 15;173(10):6017-24. doi: 10.4049/jimmunol.173.10.6017. J Immunol. 2004. PMID: 15528336
-
Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor.Eur J Immunol. 2006 Dec;36(12):3167-74. doi: 10.1002/eji.200636550. Eur J Immunol. 2006. PMID: 17109472
-
Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy.Curr Gene Ther. 2001 Sep;1(3):253-5. doi: 10.2174/1566523013348607. Curr Gene Ther. 2001. PMID: 12109140 Review.
-
Mitochondrial control of caspase-dependent and -independent cell death.Cell Mol Life Sci. 2010 May;67(10):1589-97. doi: 10.1007/s00018-010-0285-y. Epub 2010 Feb 12. Cell Mol Life Sci. 2010. PMID: 20151314 Free PMC article. Review.
Cited by
-
Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.Vaccines (Basel). 2022 Sep 7;10(9):1493. doi: 10.3390/vaccines10091493. Vaccines (Basel). 2022. PMID: 36146572 Free PMC article. Review.
-
Kirenol attenuates experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells.Sci Rep. 2015 Mar 12;5:9022. doi: 10.1038/srep09022. Sci Rep. 2015. PMID: 25762107 Free PMC article.
-
Cell-mediated immune resistance in cancer.Cancer Drug Resist. 2020;3(2):232-251. doi: 10.20517/cdr.2019.98. Epub 2020 Jan 2. Cancer Drug Resist. 2020. PMID: 35310881 Free PMC article.
-
Targeting Type 1 Diabetes: Selective Approaches for New Therapies.Biochemistry. 2019 Jan 29;58(4):214-233. doi: 10.1021/acs.biochem.8b01118. Epub 2019 Jan 17. Biochemistry. 2019. PMID: 30608114 Free PMC article. Review.
-
Death receptor-independent activation-induced cell death in human melanoma antigen-specific MHC class I-restricted TCR-engineered CD4 T cells.J Immunol. 2013 Sep 15;191(6):3471-7. doi: 10.4049/jimmunol.1202350. Epub 2013 Aug 9. J Immunol. 2013. PMID: 23935194 Free PMC article.
References
-
- van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–1647. - PubMed
-
- Mukherji B, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol. 1995;7(2):175–184. - PubMed
-
- Nouri-Shirazi M, Banchereau J, Fay J, Palucka K. Dendritic cell based tumor vaccines. Immunol Lett. 2000;74(1):5–10. - PubMed
-
- Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: Current status and future directions. Vaccine. 2007 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources